Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Inotuzumab Ozogamicin Plus Chemotherapy in Older Ph-negative CD22+ B-cell Precursor ALL
2016-004942-27Phase 2Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Jul 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Centre Hospitalier de Versailles. Started Jul 2017; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2016-004942-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004942-27.